Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

U.S. pharmaceutical giant Eli Lilly (LLY) is lowering the cost of its blockbuster weight loss medication Zepbound in an effort to reach more ...

Many employers and insurers are scaling back coverage and Medicare doesn’t cover the drugs for obesity. Meantime, some big ...

Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...

Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes ...

United Health Group, the largest U.S. health insurer by enrollees, was under pressure after Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, sent the conglomerate's chief executive, ...

Eli Lily's GLP-1 competitor Mounjaro/Zepbound doesn't make the list ... Inflation Reduction Act is lowering prices for people on Medicare. HHS will continue negotiating in the best interest ...

Eli Lilly says new research shows its medication Zepbound helped patients shed more ... of anti-obesity medications for Americans with Medicare and Medicaid. A shortage in injections linked ...

She also noted, “Zepbound, the tirzepatide label for weight ... Last year, the Biden administration announced plans for Medicaid and Medicare to cover Ozempic and Wegovy for obese people ...

Medicare’s block on obesity medication coverage ... like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), which generally have to be paid for out-of-pocket as ...

Lilly's Zepbound tops Wegovy for weight loss in head ... for more than 7 million people with Medicare and Medicaid health coverage, which could cut out-of-pocket expenses for some by as much ...